People behind Keen Eye
CEO & Founder
People Operations Manager
Lead Developer Front End
Chief Technology Officer
Quality Assurance Engineer
Talent Acquisition Manager
Lead Product Owner
Machine Learning Engineer
Head of Infrastrucure
Head of Data Science
Sylvain Berlemont, PhD
CEO and Founder
Sylvain believes in the power of machine learning and computer vision to improve the everyday life of biologists, doctors and patients. At Keen Eye, he transmits his leadership spirit to an enthusiastic and talented team that strives for high performance in the products they create.
Prior to founding Keen Eye, Sylvain completed a PhD in biomedical image analysis from Pasteur Institute, Paris, and a computer science degree from EPITA. He began his career as a postdoctoral fellow, first at the Scripps Research Institute, San Diego CA, and then at Harvard Medical School, Boston MA. He then transitioned into entrepreneurship as the CTO and co-founder of a digital health company based in the US.
Strategic Advisory Board
Pr Gaudenz Danuser, PhD
Professor and Chairman at UT Southwestern Medical Center
Gaudenz Danuser is the inaugural chair of the Lyda Hill Department of Bioinformatics. He also holds the Patrick E. Haggerty Distinguished Chair in Basic Biomedical Science and is a Scholar of the Cancer Prevention Institute of Texas. He is co-chair of the computational and systems biology track in UTSW’s graduate school. Before moving to UTSW, Danuser directed research laboratories at ETH Zurich, at The Scripps Research Institute in La Jolla, and at Harvard Medical School. He completed a PhD in Electrical Engineering, before entering the field of cell biology as a postdoctoral fellow at the MBL in Woods Hole. His contributions to cell biology and biophysics have been recognized by several awards and honors.
Former Executive Vice President at Sanofi
Ms. Witz brings over 20 years of global healthcare management experience to the Board. She most recently served as executive vice president, global diabetes and cardiovascular at Sanofi. During her tenure at Sanofi, she launched multiple medicines and strengthened the pipeline through licensing and partnerships. Prior to Sanofi, Ms. Witz served 17 years at GE Healthcare which included her final role as president and chief executive officer of its medical diagnostics business, a $2 billion integrated pharmaceutical organization that spanned from R&D to commercialization. She received her MBA in Economics and Marketing from INSEAD and her MS in Biochemistry from INSA Lyon.
Executive Chairwoman at CM-CIC Innovation
Karine Lignel, after an industrial career in the food industry, became a Venture Capitalist in 2000. Her field of expertise is fast-growing technological companies. Since then, she has chosen and invested in more than 35 companies and been in charge of a total of more than 60 companies which she has helped on their strategic plans. Karine has been an active member of more than 30 Boards. She has been heavily involved in the refinancing rounds and has been instrumental in three industrial exits as well as two successful IPOs. Karine is the Executive Chairwoman of CM-CIC Innovation, which has an active portfolio of 38 companies, and an Executive Director of CM-CIC Investissement. Karine has a Food Engineer Degree (ENSIA, Massy) as well as an MBA in Finance and Accounting (IGIA, Cergy).
Partner at Seventure Partners
Philippe Tramoy joined Seventure Partners in November 2013 as Investment director within Quadrivium 1 seed fund team. He is in charge of this fund’s investments in the Life Sciences sector.He has 15 years experience as an entrepreneur and business developer in Startup and corporate. In 2004, he founded and managed a market and business intelligence company, CBDMT – Market & Business Intelligence. Philippe Tramoy is graduated in biochemistry and in immunology & genetics from the Burgundy’s University and the Ecole Normale Supérieure in Lyon. He is also graduated from IAE Paris Panthéon-Sorbonne and HEC Paris.
Medical Advisory Board
Philippe Vielh, MD, PhD
Medipath and American Hospital of Paris
Dr. Philippe Vielh, directed the cytopathology unit at Institut Curie for 13 years before moving to Gustave Roussy cancer center where he headed the cytopathology unit from 2003 until 2015, the histocytopathology unit of the translational research laboratory (2007-2014), and the institutional biobank (2011-2014). His current affiliation is at Medipath, working at the American Hospital of Paris to establish a one-day clinic for breast and thyroid lesions. Pr. Vielh is Professor of Pathology at the Porto Faculty of Medicine and his research interests are the application of omics and of artificial intelligence technologies in Pathology.
Jacques Bosq, MD, PhD
Former Head of Pathology at Institut Gustave Roussy, France
Jacques Bosq is a Specialist Pathologist at the Centres de Lutte Contre le Cancer. He previously held the position of Head of Biology and Medical Pathology Departments and Head of Service of Medical Morphology at the Institute Gustave Roussy. He has over 30 years of experience in practicing oncological pathology and the Gustave Roussy Institute. He participated a variety of activities from clinical work to translational research to teaching. Today he is a consultant pathologist particularly interested in the study of bio-marker expressions and digital pathology in the pre-clinical and translational research sector.